why choose us

First received: May 14, 2023

Clinical Trial: Cladribine Plus Homoharringtonine and Cytarabine Regimen (CHA) for de Novo Acute Myeloid Leukemia

Study Status: Completed

Recruit Status: RECRUITING

Condition: Acute Myeloid Leukemia, Adult

Study Type: INTERVENTIONAL


Official Title: A Monocenter Prospective Single Arm Study of Cladribine Plus Homoharringtonine and Cytarabine Regimen (CHA) for Induced Therapy in Adults de Novo Acute Myeloid Leukemia (Non-M3)

Brief Summary: The goal of this clinical trial is to evaluate the response and safety of Cladribine plus Homoharringtonine and Cytarabine regimen (CHA) protocol in de novo acute myeloid leukemia with age <60y.This is a prospective, single-armed mono-center based investigator-initiated trial.About 30 patients who meet the enrollment criteria with be treated with CHA as induction chemotherapy.The complete response rate, survival rate, recurrence rate, and treatment-related mortality with be observed.

Read more